Nanoparticles in endothelial theranostics

Pharmacological Reports

Volumn 67, Issue 4, 2015, Pages 751-755

  Zapotoczny, Szczepan ^a   Szczubialka, Krzysztof ^a   Nowakowska, Maria ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Atherosclerosis; Cardiovascular diseases; Nanoparticles; Theranostics; Thrombosis

Indexed keywords

NANOPARTICLE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ANTIANGIOGENIC ACTIVITY; ATHEROSCLEROSIS; BIOLOGICAL MONITORING; BLOOD VESSEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CHEMICAL COMPOSITION; DRUG SAFETY; EMBOLISM PREVENTION; ENDOTHELIUM; HUMAN; NANOTECHNOLOGY; NANOTHERANOSTICS; OUTCOME ASSESSMENT; REVIEW; THROMBOEMBOLISM; THROMBOSIS; TOXICITY TESTING; ANIMAL; CARDIOVASCULAR DISEASES; DRUG EFFECTS; PATHOLOGY; PROCEDURES; THERANOSTIC NANOMEDICINE; TRENDS; VASCULAR ENDOTHELIUM;

ANIMALS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; NANOPARTICLES; THERANOSTIC NANOMEDICINE;

EID: 84940460974     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2015.05.018     Document Type: Review

References (77)

1. M. Bhushan Springer handbook of nanotechnology 3rd ed. 2010 Springer-Verlag Berlin
2. A.L.B. Barros, and D.C.F. Soares Theranostic nanoparticles: imaging and therapy combined J Mol Pharm Org Process Res 2 2014 e113
3. I. Cicha, C.D. Garlichs, and C. Alexiou Cardiovascular therapy through nanotechnology - how far are we still from bedside? Eur J Nanomed 6 2 2014 63 87
4. A. Puri, and R. Blumenthal Polymeric lipid assemblies as novel theranostic tools Accounts Chem Res 44 2011 1071 1079
5. B. Sumer, and J. Gao Theranostic nanomedicine for cancer Nanomedicine 3 2008 137 140
6. H. Koo, M.S. Huh, I.C. Sun, S.H. Yuk, K. Choi, K. Kim, and et al. In vivo targeted delivery of nanoparticles for theranosis Accounts Chem Res 44 2011 1018 1028
7. L.S. Wang, M.C. Chuang, and J.A. Ho Nanotheranostics - a review of recent publications Int J Nanomed 7 2012 4679 4695
8. I. Brigger, C. Dubernet, and P. Couvreur Nanoparticles in cancer therapy and diagnosis Adv Drug Delivery Rev 54 2002 631 651
9. European Cardiovascular Disease Statistics 2012 edition. Brussels/Sophia Antipolis: European Heart Network (www.ehnheart.org) and European Society of Cardiology (www.escardio.org) 2012
10. J. Tang, M.E. Lobatto, J.C. Read, A.J. Mieszawska, Z.A. Fayad, and W.J.M. Mulder Nanomedical theranostics in cardiovascular disease Curr Cardiovasc Imag Rep 5 2012 19 25
11. R. Ross Atherosclerosis is an inflammatory disease Am Heart J 138 1999 S419e20
12. E. Falk Pathogenesis of atherosclerosis J Am Coll Cardiol 47 8 Suppl. C 2006 7 12
13. S. Santra, S.D. Jativa, C. Kaittanis, O.J. Santiesteban, G. Normand, J. Grimm, and et al. Gadolinium-encapsulating iron oxide nanoprobe as activatable NMR/MRI contrast agent ACS Nano 8 2012 7281 7294
14. H. Yanga, Y. Zhuanga, Y. Sund, A. Dai, X. Shi, D. Wue, and et al. Targeted dual-contrast T1- and T2-weighted magnetic resonance imaging of tumors using multifunctional gadolinium-labeled superparamagnetic iron oxide nanoparticles Biomaterials 32 2011 4584 5459
15. T. Panczyk, T. Konczak, S. Zapotoczny, P. Szabelski, and M. Nowakowska Molecular dynamics simulations of proton transverse relaxation times in suspensions of magnetic nanoparticles J Colloid Interfaces Sci 473 1 2015 187 196
16. S.S. De Chou, H.M. Joshi, and V.P. Dravid Hybrid magnetic nanostructures (MNS) for magnetic resonance imaging applications Adv Drug Deliv Rev 63 2011 1282 1299
17. A. Szpak, S. Fiejdasz, W. Prendota, T. Strączek, C. Kapusta, J. Szmyd, and et al. T1-T2 Dual-modal MRI contrast agents based on superparamagnetic iron oxide nanoparticles with surface attached gadolinium complexes J Nanopart Res 16 2014 2678
18. A. Szpak, G. Kania, T. Skórka, W. Tokarz, S. Zapotoczny, and M. Nowakowska Stable aqueous dispersion of superparamagnetic iron oxide nanoparticles protected by charged chitosan derivatives J Nanopart Res 15 2013 1372 1386
19. J. Lewandowska, M. Staszewska, M. Kepczynski, M. Szuwarzyński, A. Łatkiewicz, Z. Olejniczak, and et al. Sol-gel synthesis of iron oxide-silica composite microstructures J Sol Gel Sci Technol 64 2012 67 77
20. J. Lewandowska-Łancucka, M. Staszewska, M. Szuwarzynski, M. Kepczynski, M. Romek, W. Tokarz, and et al. Synthesis and characterization of the superparamagnetic iron oxide nanoparticles modified with cationic chitosan and coated with silica shell J Alloys Compd 586 2014 45 51
21. Z.R. Stephen, F.M. Kievit, and M. Zhang Magnetite nanoparticles for medical MR imaging Mater Today 7-8 2011 330 338
22. K.A. Kelly, J.R. Allport, A. Tsourkas, V.R. Shinde-Patil, L. Josephson, and R. Weissleder Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle Circ Res 96 2005 327 336
23. M. Nahrendorf, F.A. Jaffer, K.A. Kelly, D.E. Sosnovik, E. Aikawa, P. Libby, and et al. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis Circulation 114 2006 1504 1511
24. P.R. Reynolds, D.J. Larkman, D.O. Haskard, J.V. Hajnal, N.L. Kennea, A.J. George, and et al. Detection of vascular expression of E-selectin in vivo with MR imaging Radiology 241 2006 469 476
25. M.J. Jacobin-Valat, K. Deramchia, S. Mornet, C.E. Hagemeyer, S. Bonetto, R. Robert, and et al. MRI of inducible P-selectin expression in human activated platelets involved in the early stages of atherosclerosis NMR Biomed 24 2011 413 424
26. M.E. Kooi, V.C. Cappendijk, K.B. Cleutjens, A.G. Kessels, P.J. Kitslaar, M. Borgers, and et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging Circulation 107 19 2003 2453 2458
27. S.G. Ruehm, C. Corot, P. Vogt, S. Kolb, and J.F. Debatin Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits Circulation 103 3 2001 415 422
28. A. Millon, E. Canet-Soulas, L. Boussel, Z. Fayad, and P. Douek Animal models of atherosclerosis and magnetic resonance imaging for monitoring plaque progression Vascular 2013 1 17
29. G. Stoll, and M. Bendszus Inflammation and atherosclerosis: novel insights into plaque formation and destabilization Stroke 37 2006 1923 1932
30. J.B. Michel, S. Delbosc, B. Ho-Tin-Noé, G. Leseche, A. Nicoletti, O. Meilhac, and et al. From intraplaque haemorrhages to plaque vulnerability: biological consequences of intraplaque haemorrhages J Cardiovasc Med 13 10 2012 628 634
31. J.J. Wentzel, Y.S. Chatzizisis, F.J. Gijsen, G.D. Giannoglou, C.L. Feldman, and P.H. Stone Endothelial shear stress in the evolution of coronary atherosclerotic plaque and vascular remodelling: current understanding and remaining questions Cardiovasc Res 96 2012 234 243
32. F. Crea, and G. Liuzzo Pathogenesis of acute coronary syndromes J Am Coll Cardiol 61 2013 1 11
33. J.E. Muller, A. Tawakol, S. Kathiresan, and J. Narula New opportunities for identification and reduction of coronary risk: treatment of vulnerable patients, arteries, and plaques J Am Coll Cardiol 47 8 Suppl. 2006 C2 C6
34. J.A. Ambrose In search of the "vulnerable plaque": can it be localized and will focal regional therapy ever be an option for cardiac prevention? J Am Coll Cardiol 51 16 2008 1539 1542
35. M.E. Lobatto, Z.A. Fayad, S. Silvera, E. Vucic, C. Calcagno, V. Mani, and et al. Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis Mol Pharm 7 6 2010 2020 2029
36. A. Millon, S.D. Dickson, A. Klink, D. Izquierdo-Garcia, J. Bini, E. Lancelot, and et al. Monitoring plaque inflammation in atherosclerotic rabbits with an iron oxide (P904) and 18F-FDG using a combined PET/MR scanner Atherosclerosis 228 2013 339e345
37. M. Puato, E. Faggin, M. Rattazzi, A. Zambon, F. Cipollone, F. Grego, and et al. Atorvastatin reduces macrophage accumulation in atherosclerotic plaques: a comparison of a nonstatin-based regimen in patients undergoing carotid endarterectomy Stroke 41 2010 1163e8
38. M. Crisby, G. Nordin-Fredriksson, P.K. Shah, J. Yano, J. Zhu, and J. Nilsson Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization Circulation 103 2001 926 933
39. W. Chen, D. Cormode, Y. Vengrenyuk, B. Herranz, J.E. Feig, A. Klink, and et al. Collagen-specific peptide conjugated HDL nanoparticles as MRI contrast agent to evaluate compositional changes in atherosclerotic plaque regression JACC Cardiovasc Imag 6 3 2013 373 384
40. J. Hamzah, V.R. Kotamraju, J.W. Seo, L. Agemy, V. Fogal, L.M. Mahakian, and et al. Specific penetration and accumulation of a homing peptide within atherosclerotic plaques of apolipoprotein E-deficient mice Proc Natl Acad Sci USA 108 2011 7154 7159
41. M. Uchida, H. Kosuge, M. Terashima, D.A. Willits, L.O. Liepold, M.J. Young, and et al. Protein cage nanoparticles bearing the LyP-1 peptide for enhanced imaging of macrophage-rich vascular lesions ACS Nano 5 2011 2493 2502
42. C. Tu, T.S. Ng, H.K. Sohi, H.A. Palko, A. House, R.E. Jacobs, and et al. Receptor-targeted iron oxide nanoparticles for molecular MR imaging of inflamed atherosclerotic plaques Biomaterials 32 2011 7209 7216
43. S. Wen, D.F. Liu, Z. Liu, S. Harris, Y.Y. Yao, Q. Ding, and et al. OxLDL-targeted iron oxide nanoparticles for in vivo MRI detection of perivascular carotid collar induced atherosclerotic lesions in ApoE-deficient mice J Lipid Res 53 2012 829 838
44. G.A. van Tilborg, E. Vucic, G.J. Strijkers, D.P. Cormode, V. Mani, T. Skajaa, and et al. Annexin A5-functionalized bimodal nanoparticles for MRI and fluorescence imaging of atherosclerotic plaques Bioconjug Chem 21 2010 1794 1803
45. M. Jeziorska, and D.E. Woolley Neovascularization in early atherosclerotic lesions of human carotid arteries: its potential contribution to plaque development Hum Pathol 30 8 1999 919 925
46. P.R. Moreno, R. Purushothaman, V. Fuster, D. Echeverri, H. Truszczynska, S.K. Sharma, and et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability Circulation 110 14 2004 2032 2038
47. R. Mofidi, T.B. Crotty, P. McCarthy, S.J. Sheehan, D. Mehigan, and T.V. Keaveny Association between plaque instability, angiogenesis and symptomatic carotid occlusive disease Br J Surg 88 7 2001 945 950
48. F.D. Kolodgie, H.K. Gold, A.P. Burke, D.R. Fowler, H.S. Kruth, D.K. Weber, and et al. Intraplaque hemorrhage and progression of coronary atheroma New Engl J Med 349 24 2003 2316 2325
49. D. Ingber, T. Fujita, S. Kishimoto, K. Sudo, T. Kanamaru, H. Brem, and et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth Nature 348 6301 1990 555 557
50. P.M. Winter, A.M. Neubauer, S.D. Caruthers, T.D. Harris, J.D. Robertson, T.A. Williams, and et al. Endothelial αvβ3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis Arterioscler Thromb Vasc Biol 26 9 2006 2103 2109
51. D. Wang, B. Lin, and A. Hua Theranostic nanoparticles for cancer and cardiovascular applications Pharm Res 31 2014 1390 1406
52. H.C. Whinna Overview of murine thrombosis models Thromb Res 122 Suppl. 1 2008 S64 S69
53. D. Peters, M. Kastantin, V.R. Kotamraju, P.P. Karmali, K. Gujraty, M. Tirrell, and et al. Targeting atherosclerosis by using modular, multifunctional micelles Proc Natl Acad Sci USA 106 2009 9815 9819
54. M.R. Makowski, S.C. Forbes, U. Blume, A. Warley, C. Jansen, A. Schuster, and et al. In vivo assessment of intraplaque and endothelial fibrin in ApoE(-/-) mice by molecular MRI Atherosclerosis 222 2012 43 49
55. C.A. Cronin Intravenous tissue plasminogen activator for stroke: a review of the ECASS III results in relation to prior clinical trials J Emerg Med 38 1 2010 99 105
56. M.A. Hatcher, and J.A. Starr Role of tissue plasminogen activator in acute ischemic stroke Ann Pharmacother 45 3 2011 364 371
57. E. Bluhmki, A. Chamorro, A. Dávalos, T. Machnig, C. Sauce, N. Wahlgren, and et al. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial Lancet Neurol 8 2009 1095 1102
58. S.B. Han, S.H. Baek, J.S. Park, H.K. Yang, J.Y. Kim, C.K. Kim, and et al. Effect of subconjunctivally injected liposome-encapsulated tissue plasminogen activator on the absorption rate of subconjunctival hemorrhages in rabbits Cornea 30 12 2011 1455 1460
59. X. Hua, P. Liu, Y.H. Gao, K.B. Tan, L.N. Zhou, Z. Liu, and et al. Construction of thrombus-targeted microbubbles carrying tissue plasminogen activator and their in vitro thrombolysis efficacy: a primary research J Thromb Thrombolysis 30 2010 29 35
60. T.W. Chung, S.S. Wang, and W.J. Tsai Accelerating thrombolysis with chitosan-coated plasminogen activators encapsulated in poly-(lactide-co-glycolide) (PLGA) nanoparticles Biomaterials 29 2008 228 237
61. S.S. Wang, N.K. Chou, and T.W. Chung The t-PA-encapsulated PLGA nanoparticles shelled with CS or CS-GRGD alter both permeation through and dissolving patterns of blood clots compared with t-PA solution: an in vitro thrombolysis study J Biomed Mater Res A 91 2009 753 776
62. H.W. Yang, M.Y. Hua, K.J. Lin, S.P. Wey, R.Y. Tsai, S.Y. Wu, and et al. Bioconjugation of recombinant tissue plasminogen activator to magnetic nanocarriers for targeted thrombolysis Int J Nanomed 7 2012 5159 5173
63. J.P. Chen, P.C. Yang, Y.H. Ma, and T. Wu Characterization of chitosan magnetic nanoparticles for in situ delivery of tissue plasminogen activator Carbohydr Polym 84 2011 364 372
64. G. Huang, Z. Zhou, R. Srinivasan, M.S. Penn, K. Kottke-Marchant, R.E. Marchant, and et al. Affinity manipulation of surface-conjugated RGD peptide to modulate binding of liposomes to activated platelets Biomaterials 29 2008 1676 1685
65. R. Srinivasan, R.E. Marchant, and A.S. Gupta In vitro and in vivo platelet targeting by cyclic RGD-modified liposomes J Biomed Mater Res A 93 2010 1004 1015
66. T.W. Chung, S.S. Wang, and W.J. Tsai Accelerating thrombolysis with chitosan-coated plasminogen activators encapsulated in poly(lactide-co-glycolide) (PLGA) nanoparticles Biomaterials 29 2008 228 237
67. S.S. Wang, N.K. Chou, and T.W. Chung The t-PA-encapsulated PLGA nanoparticles shelled with CS or CS-GRGD alter both permeation through and dissolving patterns of blood clots compared with t-PA solution: an in vitro thrombolysis study J Biomed Mater Res A 91 2009 753 761
68. J. Zhou, D. Guo, Y. Zhang, W. Wu, H. Ran, and Z. Wang Construction and evaluation of Fe3O4 based PLGA nanoparticles carrying rtPA used in the detection of thrombosis and in targeted thrombolysis ACS Appl Mater Interf 6 2014 5566 5576
69. K.L. Aillon, Y. Xie, N. El-Gendy, C.J. Berkland, and M.L. Forrest Effects of nanomaterial physicochemical properties on in vivo toxicity Adv Drug Deliv Rev 61 2009 457 466
70. K.M. Hasebroock, and N.J. Serkova Toxicity of MRI and CT contrast agents Expert Opin Drug Metab Toxicol 5 2009 403 416
71. H. Bernd, E. De Kerviler, S. Gaillard, and B. Bonnemain Safety and tolerability of ultrasmall superparamagnetic iron oxide contrast agent: comprehensive analysis of a clinical development program Invest Radiol 44 2009 336 342
72. K. Buyukhatipoglu, T.A. Miller, and A.M. Clyne Flame synthesis and in vitro biocompatibility assessment of superparamagnetic iron oxide nanoparticles: cellular uptake, toxicity and proliferation studies J Nanosci Nanotechnol 9 2009 834 843
73. J.L. Winer, C.Y. Liu, and M.L. Apuzzo The use of nanoparticles as contrast media in neuroimaging: a statement on toxicity World Neurosurg 78 2012 709 711
74. U. Sadat, S.P. Howarth, A. Usman, T.Y. Tang, M.J. Graves, and J.H. Gillard Sequential imaging of asymptomatic carotid atheroma using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging: a feasibility study J Stroke Cerebrovasc Dis 22 2013 e271 e276
75. E.A. Neuwelt, B.E. Hamilton, C.G. Varallyay, W.R. Rooney, R.D. Edelman, P.M. Jacobs, and et al. Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)? Kidney Int 75 2009 465 474
76. J.D. López-Castro, A.V. Maraloiu, J.J. Delgado, J.J. Calvino, M.G. Blanchin, N. Gálvezd, and et al. From synthetic to natural nanoparticles: monitoring the biodegradation of SPIO (P904) into ferritin by electron microscopy Nanoscale 3 2011 4597 4599
77. J.B. Hall, M.A. Dobrovolskaia, A.K. Patri, and S.E. McNeil Characterization of nanoparticles for therapeutics Nanomedicine 2 2007 789 803